Agentix (AGTX) Research & Development (2013 - 2026)
Agentix's (AGTX) quarterly Research & Development came in at $25079.0 in Q3 2025, up 111.64% YoY from $11850.0 in Q3 2024, and down 74.92% on a QoQ basis from $100000.0 in Q2 2025.
Agentix (AGTX) Research & Development (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 11 years of Research & Development data on file, last reported at $25079.0 in Q3 2025.
- Quarterly Research & Development rose 111.64% year-over-year to $25079.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $125079.0 (down 30.89% YoY) and the FY2026 annual result came in at $125079.0, down 30.89% from the prior year.
- Research & Development fell to $25079.0 in Q3 2025, from $100000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $284532.0 in Q3 2022 to a low of -$87304.0 in Q4 2023.
- A 5-year average of $87872.8 and a median of $58366.0 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 209.48% in 2023, down 145.46% in 2023.
- Tracing AGTX's Research & Development over 5 years: stood at $42950.0 in 2021, then soared by 347.11% to $192032.0 in 2022, then plunged by 145.46% to -$87304.0 in 2023, then surged by 126.67% to $23287.0 in 2024, then climbed by 7.7% to $25079.0 in 2025.
- The last three Research & Development figures came in at $25079.0 (Q3 2025), $100000.0 (Q2 2025), and $90349.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 16,635.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,635.00 |
| Sep 30, 2025 | 25,079.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 90,349.00 |
| Dec 31, 2024 | 23,287.00 |
| Sep 30, 2024 | 11,850.00 |
| Jun 30, 2024 | 55,501.00 |
| Mar 31, 2024 | 46,024.00 |
| Dec 31, 2023 | -87,304.00 |
| Sep 30, 2023 | 58,366.00 |
| Jun 30, 2023 | 158,182.00 |
| Mar 31, 2023 | 183,830.00 |
| Dec 31, 2022 | 192,032.00 |
| Sep 30, 2022 | 284,532.00 |
| Jun 30, 2022 | 51,112.00 |
| Feb 28, 2022 | 84,050.00 |
| Nov 30, 2021 | 42,950.00 |
| Aug 31, 2021 | 113,912.00 |
| May 31, 2021 | 57,500.00 |
| Feb 28, 2021 | 178,332.00 |